Information Provided By: 
Fly News Breaks for April 3, 2017
ACOR
Apr 3, 2017 | 07:21 EDT
As previously reported, Janney Capital analyst Ken Trbovich downgraded Acorda Therapeutics to Neutral from Buy after a district court upheld one Ampyra patent that expires in 2018 but invalidated four others that would have delayed generic competition into the mid 2020s. While there is "some reason for hope on appeal," Acorda must now prepare for a generic Ampyra coming in 2018, said Trbovich, who lowered his fair value estimate for the stock to $19 from $38.
News For ACOR From the Last 2 Days
There are no results for your query ACOR
